Nouscom
is a Switzerland-based immuno-oncology company that researches and develops personalized immunotherapies for the treatment of cancer... Read moreNouscom
is a Switzerland-based immuno-oncology company that researches and develops personalized immunotherapies for the treatment of cancer... Read more
News
Apr 29, 2025
GlobalNewswire
Press Release: Nouscom : Nouscom Presents Positive Final Results from Completed Phase Ib/II Study of Neoantigen Immunotherapy NOUS-209 at AACR 2025, Demonstrating a Highly Potent and Durable Immune Response in Lynch Syndrome Carriers
Mar 26, 2025
PharmaTimes
Nouscom: Nouscom reveals promising results for lynch syndrome immunotherapy
Nov 19, 2024
StreetInsider
Press Release: Nouscom : Nouscom Completes Patient Enrollment of Randomized Phase 2 Study Evaluating NOUS-209, an Off-the-Shelf Neoantigen Immunotherapy, in dMMR/MSI Metastatic Colorectal Cancer
Nov 05, 2024
GlobalNewswire
Press Release: Nouscom : Nouscom's Off-the-Shelf Neoantigen Immunotherapy, NOUS-209, Continues to Elicit Potent and Durable Immune Responses in Lynch Syndrome Carriers Highlighting its Potential to 'Intercept' Cancer
Mar 26, 2024
startupticker ch
Nouscom: Nouscom secures additional funding from Angelini Ventures
Mar 21, 2024
Clinical Trials Arena
Nouscom: Nouscom extends Series C round to $82m for cancer vaccine trials
Oct 31, 2023
GlobalNewswire
Press Release: Nouscom : Nouscom's Off-the-Shelf Cancer Vaccine, NOUS-209, Shows Potential to 'Intercept' Cancer in Subjects with Lynch Syndrome
Apr 18, 2023
Life Care News
Nouscom: Nouscom Presents New Positive Translational Phase 1b Data
Mar 15, 2023
StreetInsider
Press Release: Nouscom : Nouscom Announces AACR 2023 Late-Breaking Presentation of Translational Phase 1b Data of NOUS-PEV, a Personalized Neoantigen Cancer Immunotherapy
Jan 09, 2023
startupticker
Nouscom: Nouscom and MSD sign a clinical trial and supply agreement
Nouscom Competitors
1
2
3
4
5
6
7